Clinical Trial: A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I

U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07554924) titled 'A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I' on April 21.

Brief Summary: This is a phase I/II clinical study to evaluate the safety, preliminary efficacy and immunogenicity of SKG0201 injection in subjects with Spinal Muscular Atrophy Type I.

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: Spinal Muscular Atrophy 1

Intervention: GENETIC: SKG0201 Injection

SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based gene therapy product.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Lanyue Biotech (Hangzhou) Co., Ltd.

Disclaimer: Curated ...